Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q7LG56
UPID:
RIR2B_HUMAN
Alternative names:
TP53-inducible ribonucleotide reductase M2 B; p53-inducible ribonucleotide reductase small subunit 2-like protein
Alternative UPACC:
Q7LG56; B4E2N4; Q17R22; Q75PQ6; Q75PQ7; Q75PY8; Q75PY9; Q86YE3; Q9NPD6; Q9NTD8; Q9NUW3
Background:
The Ribonucleoside-diphosphate reductase subunit M2 B, also known as TP53-inducible ribonucleotide reductase M2 B, plays a crucial role in cell survival by repairing damaged DNA in a p53/TP53-dependent manner. It is essential for supplying deoxyribonucleotides for DNA repair in cells arrested at G1 or G2 phases and contains an iron-tyrosyl free radical center required for catalysis.
Therapeutic significance:
This protein's involvement in mitochondrial DNA depletion syndromes 8A and 8B, progressive external ophthalmoplegia, and rod-cone dystrophy highlights its potential as a target for therapeutic strategies aimed at mitigating mitochondrial dysfunction and related diseases.